Literature DB >> 19497995

The influence of tumor-host interactions in the stromal cell-derived factor-1/CXCR4 ligand/receptor axis in determining metastatic risk in breast cancer.

Saima Hassan1, Cristiano Ferrario, Uri Saragovi, Louise Quenneville, Louis Gaboury, Andrea Baccarelli, Ombretta Salvucci, Mark Basik.   

Abstract

The chemokine stromal cell-derived factor-1 (SDF-1) may function to attract CXCR4-expressing cancer cells to metastatic organs. We have previously demonstrated that low plasma SDF-1, a host-derived marker, increases distant metastatic risk in breast cancer. We therefore hypothesized that tumors overexpressing the SDF-1 receptor CXCR4 have an enhanced ability to metastasize in patients with low plasma SDF-1 levels. In this study, we determined the prognostic significance of activated CXCR4, or phosphorylated CXCR4 (p-CXCR4), and CXCR7, another receptor for SDF-1. Immunohistochemistry was performed on a tissue microarray built using 237 samples from the same cohort of patients for which we measured plasma SDF-1 levels. We found that the prognostic value of p-CXCR4 expression (hazard ratio or HR, 3.95; P = 0.004) was superior to total CXCR4 expression (HR, 3.20; P = 0.03). The rate of breast cancer-specific mortality was much higher in patients with both high p-CXCR4 expression and low plasma SDF-1 levels (HR, 5.96; P < 0.001) than either low plasma SDF-1 (HR, 3.59; P = 0.01) or high p-CXCR4 expression (HR, 3.83; P = 0.005) alone. The added prognostic value of low plasma SDF-1 was only effective in patients with high p-CXCR4 expression, and as such, provides clinical validation for modulation of the metastatic potential of tumor cells by an inherent host-derived metastatic risk factor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19497995      PMCID: PMC2708795          DOI: 10.2353/ajpath.2009.080948

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  27 in total

Review 1.  The bicyclam AMD3100 story.

Authors:  Erik De Clercq
Journal:  Nat Rev Drug Discov       Date:  2003-07       Impact factor: 84.694

2.  Involvement of chemokine receptors in breast cancer metastasis.

Authors:  A Müller; B Homey; H Soto; N Ge; D Catron; M E Buchanan; T McClanahan; E Murphy; W Yuan; S N Wagner; J L Barrera; A Mohar; E Verástegui; A Zlotnik
Journal:  Nature       Date:  2001-03-01       Impact factor: 49.962

3.  The distribution of secondary growths in cancer of the breast. 1889.

Authors:  S Paget
Journal:  Cancer Metastasis Rev       Date:  1989-08       Impact factor: 9.264

4.  The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases.

Authors:  Roderick J Phillips; Marie D Burdick; Marin Lutz; John A Belperio; Michael P Keane; Robert M Strieter
Journal:  Am J Respir Crit Care Med       Date:  2003-03-05       Impact factor: 21.405

5.  X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.

Authors:  Robert L Camp; Marisa Dolled-Filhart; David L Rimm
Journal:  Clin Cancer Res       Date:  2004-11-01       Impact factor: 12.531

Review 6.  The significance of cancer cell expression of the chemokine receptor CXCR4.

Authors:  Fran Balkwill
Journal:  Semin Cancer Biol       Date:  2004-06       Impact factor: 15.707

7.  Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases.

Authors:  Su Young Kim; Chih Hung Lee; Brieanne V Midura; Choh Yeung; Arnulfo Mendoza; Sung Hyeok Hong; Ling Ren; Donald Wong; Walter Korz; Ahmed Merzouk; Hassan Salari; Hong Zhang; Sam T Hwang; Chand Khanna; Lee J Helman
Journal:  Clin Exp Metastasis       Date:  2007-12-11       Impact factor: 5.150

8.  Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4.

Authors:  Zhongxing Liang; Tao Wu; Hong Lou; Xiwen Yu; Russell S Taichman; Stephen K Lau; Shuming Nie; Jay Umbreit; Hyunsuk Shim
Journal:  Cancer Res       Date:  2004-06-15       Impact factor: 12.701

9.  Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis.

Authors:  Merav Darash-Yahana; Eli Pikarsky; Rinat Abramovitch; Evelyne Zeira; Boaz Pal; Rebekah Karplus; Katia Beider; Shani Avniel; Shafika Kasem; Eithan Galun; Amnon Peled
Journal:  FASEB J       Date:  2004-06-04       Impact factor: 5.191

10.  Tissue microarrays for high-throughput molecular profiling of tumor specimens.

Authors:  J Kononen; L Bubendorf; A Kallioniemi; M Bärlund; P Schraml; S Leighton; J Torhorst; M J Mihatsch; G Sauter; O P Kallioniemi
Journal:  Nat Med       Date:  1998-07       Impact factor: 53.440

View more
  28 in total

1.  Bone morphogenetic protein 4 (BMP4) is required for migration and invasion of breast cancer.

Authors:  Dan Guo; Jiayi Huang; Jianping Gong
Journal:  Mol Cell Biochem       Date:  2011-12-14       Impact factor: 3.396

Review 2.  Chemokines and chemokine receptors: update on utility and challenges for the clinician.

Authors:  Ishan Roy; Douglas B Evans; Michael B Dwinell
Journal:  Surgery       Date:  2014-02-08       Impact factor: 3.982

3.  Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis.

Authors:  Yixin Liu; Ru Ji; Jingyong Li; Qiang Gu; Xiulan Zhao; Tao Sun; Jinjing Wang; Jiangbo Li; Qiuyue Du; Baocun Sun
Journal:  J Exp Clin Cancer Res       Date:  2010-02-24

Review 4.  Cell migration on planar and three-dimensional matrices: a hydrogel-based perspective.

Authors:  Lucas T Vu; Gaurav Jain; Brandon D Veres; Padmavathy Rajagopalan
Journal:  Tissue Eng Part B Rev       Date:  2014-08-19       Impact factor: 6.389

5.  Breast cancer at bone metastatic sites: recent discoveries and treatment targets.

Authors:  Osama Hussein; Svetlana V Komarova
Journal:  J Cell Commun Signal       Date:  2011-01-19       Impact factor: 5.782

6.  Prognostic significance of CXCL12, CXCR4, and CXCR7 in patients with breast cancer.

Authors:  Wei Wu; Liyuan Qian; Xuedong Chen; Boni Ding
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

7.  Phosphorylated CXCR4 expression has a positive prognostic impact in colorectal cancer.

Authors:  B Weixler; F Renetseder; I Facile; N Tosti; E Cremonesi; A Tampakis; T Delko; S Eppenberger-Castori; A Tzankov; G Iezzi; C Kettelhack; S D Soysal; U von Holzen; G C Spagnoli; L Terracciano; L Tornillo; Raoul A Droeser; S Däster
Journal:  Cell Oncol (Dordr)       Date:  2017-09-21       Impact factor: 6.730

8.  Survival outcomes in endometrial cancer patients are associated with CXCL12 and estrogen receptor expression.

Authors:  Ashley S Felix; Roslyn A Stone; Mamatha Chivukula; Robert Bowser; Anil V Parwani; Faina Linkov; Robert P Edwards; Joel L Weissfeld
Journal:  Int J Cancer       Date:  2012-01-03       Impact factor: 7.396

9.  Downregulation of CXCR7 inhibits proliferative capacity and stem cell-like properties in breast cancer stem cells.

Authors:  Xin Tang; Xiang Li; Zitao Li; Yunshuang Liu; Lihong Yao; Shuang Song; Hongyan Yang; Caijuan Li
Journal:  Tumour Biol       Date:  2016-07-27

Review 10.  The intricate role of CXCR4 in cancer.

Authors:  Samit Chatterjee; Babak Behnam Azad; Sridhar Nimmagadda
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.